The European life sciences industry has a long history. Many of the major players trace their roots to before the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions.
In the past year or so, life sciences companies have outperformed the stock exchange significantly. Though it would be foolish to call this a boom time for the industry, investors know that there is money to be made in developing innovative biotech solutions.
Countries that have not been traditional life sciences powerhouses are wising up, and the next great success story seems as likely to be from India as from Europe. In this context, the traditional powerhouses of the European life sciences industry will need to be smart, while national and regional governments have to think carefully about how to keep them competitive on the global stage.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org
Bayer, biotechnology, pharmaceuticals, Astra,